{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:24:20Z","timestamp":1786123460409,"version":"build-2736575974"},"reference-count":144,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:p>A serious adverse effect of prescription opioid analgesics is addiction, both to these analgesics and to illicit drugs like heroin that also activate the \u00b5-opioid receptor (MOR). Opioid use disorder (OUD) and opioid overdose deaths represent a current American health crisis, and the prescription of opioid analgesics has contributed significantly to this crisis. While prescription opioids are highly effective analgesics, there currently exists no facile way to use them for extended periods without the risk of addiction. If addiction caused by MOR-targeting analgesics could be blocked by blending in a new \u201cantiaddiction\u201d ingredient that does not diminish analgesia and does not introduce its own therapeutically limiting side effects, then continued clinical use of prescription opioids for treating pain could be maintained (or even enhanced) instead of curtailed. In this narrative review, we contextualize this hypothesis, first with a brief overview of the current American opioid addiction crisis. The neurobiology of 2 key receptors in OUD development, MOR and the \u03ba-opioid receptor (KOR), is then discussed to highlight the neuroanatomical features and circuitry in which signal transduction from these receptors lie in opposition\u2014creating opportunities for pharmacological intervention in curtailing the addictive potential of MOR agonism. Prior findings with mixed MOR\/KOR agonists are considered before exploring new potential avenues such as biased KOR agonists. New preclinical data are highlighted, demonstrating that the G protein\u2013biased KOR agonist nalfurafine reduces the rewarding properties of MOR-targeting analgesics and enhances MOR-targeting analgesic-induced antinociception. Finally, we discuss the recent discovery that a regulator of G protein signaling (namely, RGS12) is a key component of signaling bias at KOR, presenting another drug discovery target toward identifying a single agent or adjuvant to be added to traditional opioid analgesics that could reduce or eliminate the addictive potential of the latter drug.<\/jats:p>","DOI":"10.1213\/ane.0000000000005309","type":"journal-article","created":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T19:01:36Z","timestamp":1608145296000},"page":"406-419","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":31,"title":["Potential for Kappa-Opioid Receptor Agonists to Engineer Nonaddictive Analgesics: A Narrative Review"],"prefix":"10.1213","volume":"132","author":[{"given":"Shane W.","family":"Kaski","sequence":"first","affiliation":[{"name":"Departments of Neuroscience and Behavioral Medicine & Psychiatry, West Virginia University, Morgantown, West Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison N.","family":"White","sequence":"additional","affiliation":[{"name":"Departments of Neuroscience and Behavioral Medicine & Psychiatry, West Virginia University, Morgantown, West Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Gross","sequence":"additional","affiliation":[{"name":"Department of Cell Biology, Duke University Medical Center, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Siderovski","sequence":"additional","affiliation":[{"name":"Department of Pharmacology & Neuroscience, University of North Texas Health Science Center, Fort Worth, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,12,16]]},"reference":[{"key":"R1-20250502","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1037\/a0013628","article-title":"Opioids and the treatment of chronic pain: controversies, current status, and future directions.","volume":"16","author":"Rosenblum","year":"2008","journal-title":"Exp Clin Psychopharmacol"},{"key":"R2-20250502","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.emc.2015.11.002","article-title":"The opioid epidemic in the United States.","volume":"34","author":"Wilkerson","year":"2016","journal-title":"Emerg Med Clin North Am"},{"key":"R3-20250502","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.socscimed.2004.06.044","article-title":"Innovation, diffusion and safety of a medical technology: a review of the literature on injection practices.","volume":"60","author":"Kotwal","year":"2005","journal-title":"Soc Sci Med"},{"key":"R4-20250502","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1353\/cwh.1978.0039","article-title":"Opiate addiction as a consequence of the Civil War.","volume":"24","author":"Courtwright","year":"1978","journal-title":"Civ War Hist"},{"key":"R5-20250502","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1007\/s11606-019-05559-6","article-title":"Heterogeneity in prescription opioid pain reliever misuse across age groups: 2015-2017 National Survey on Drug Use and Health.","volume":"35","author":"Schuler","year":"2020","journal-title":"J Gen Intern Med"},{"key":"R6-20250502","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0304-3959(86)90091-6","article-title":"Chronic use of opioid analgesics in non-malignant pain: report of 38 cases.","volume":"25","author":"Portenoy","year":"1986","journal-title":"Pain"},{"key":"R7-20250502","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1001\/jama.284.4.423b","article-title":"JCAHO pain management standards are unveiled.","volume":"284","author":"Phillips","year":"2000","journal-title":"JAMA"},{"key":"R8-20250502","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11916-019-0751-7","article-title":"Oxycodone\u2019s unparalleled addictive potential: is it time for a moratorium?","volume":"23","author":"Remillard","year":"2019","journal-title":"Curr Pain Headache Rep"},{"key":"R11-20250502","doi-asserted-by":"crossref","first-page":"g1251","DOI":"10.1136\/bmj.g1251","article-title":"Rates and risk factors for prolonged opioid use after major surgery: population based cohort study.","volume":"348","author":"Clarke","year":"2014","journal-title":"BMJ"},{"key":"R12-20250502","doi-asserted-by":"crossref","first-page":"e170504","DOI":"10.1001\/jamasurg.2017.0504","article-title":"New persistent opioid use after minor and major surgical procedures in US adults.","volume":"152","author":"Brummett","year":"2017","journal-title":"JAMA Surg"},{"key":"R13-20250502","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1001\/jama.2018.18472","article-title":"Opioids for chronic noncancer pain: a systematic review and meta-analysis.","volume":"320","author":"Busse","year":"2018","journal-title":"JAMA"},{"key":"R14-20250502","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.jpain.2017.06.010","article-title":"Factors influencing long-term opioid use among opioid naive patients: an examination of initial prescription characteristics and pain etiologies.","volume":"18","author":"Shah","year":"2017","journal-title":"J Pain"},{"key":"R15-20250502","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/01.j.pain.0000460357.01998.f1","article-title":"Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis.","volume":"156","author":"Vowles","year":"2015","journal-title":"Pain"},{"key":"R16-20250502","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJMra1507771","article-title":"Opioid abuse in chronic pain\u2013misconceptions and mitigation strategies.","volume":"374","author":"Volkow","year":"2016","journal-title":"N Engl J Med"},{"key":"R17-20250502","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.drugalcdep.2013.01.007","article-title":"Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers - United States, 2002-2004 and 2008-2010.","volume":"132","author":"Jones","year":"2013","journal-title":"Drug Alcohol Depend"},{"key":"R18-20250502","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0014-5793(94)80235-1","article-title":"ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization.","volume":"341","author":"Mollereau","year":"1994","journal-title":"FEBS Lett"},{"key":"R19-20250502","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1126\/science.278.5335.52","article-title":"Drug abuse: hedonic homeostatic dysregulation.","volume":"278","author":"Koob","year":"1997","journal-title":"Science"},{"key":"R20-20250502","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S2215-0366(16)00104-8","article-title":"Neurobiology of addiction: a neurocircuitry analysis.","volume":"3","author":"Koob","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"R21-20250502","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/npp.2015.258","article-title":"Dynorphin, dysphoria, and dependence: the stress of addiction.","volume":"41","author":"Chavkin","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"R22-20250502","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.pnpbp.2015.01.001","article-title":"Kappa opioid receptor signaling in the brain: circuitry and implications for treatment.","volume":"62","author":"Crowley","year":"2015","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R23-20250502","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0376-8716(98)00104-5","article-title":"Butorphanol agonist effects and acute physical dependence in opioid abusers: comparison with morphine.","volume":"53","author":"Greenwald","year":"1998","journal-title":"Drug Alcohol Depend"},{"key":"R25-20250502","doi-asserted-by":"crossref","first-page":"106105","DOI":"10.1016\/j.ypmed.2020.106105","article-title":"Leveraging black-market street buprenorphine pricing to increase capacity to treat opioid addiction, 2010-2018.","volume":"137","author":"Hswen","year":"2020","journal-title":"Prev Med"},{"key":"R26-20250502","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/nrn2947","article-title":"Neuronal circuitry for pain processing in the dorsal horn.","volume":"11","author":"Todd","year":"2010","journal-title":"Nat Rev Neurosci"},{"key":"R27-20250502","first-page":"219","article-title":"The pharmacological basis of opioids.","volume":"12","author":"Ghelardini","year":"2015","journal-title":"Clin Cases Miner Bone Metab"},{"key":"R28-20250502","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/286155a0","article-title":"Intrathecal morphine inhibits substance P release from mammalian spinal cord in vivo.","volume":"286","author":"Yaksh","year":"1980","journal-title":"Nature"},{"key":"R29-20250502","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/ana.410040511","article-title":"Endogenous pain control mechanisms: review and hypothesis.","volume":"4","author":"Basbaum","year":"1978","journal-title":"Ann Neurol"},{"key":"R30-20250502","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/0301-0082(95)00009-K","article-title":"Functional characteristics of the midbrain periaqueductal gray.","volume":"46","author":"Behbehani","year":"1995","journal-title":"Prog Neurobiol"},{"key":"R31-20250502","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1146\/annurev-med-062613-093100","article-title":"Opioid receptors.","volume":"67","author":"Stein","year":"2016","journal-title":"Annu Rev Med"},{"key":"R32-20250502","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0304-3959(83)90147-1","article-title":"A comparison of the sites at which pentazocine and morphine act to produce analgesia.","volume":"16","author":"Llewelyn","year":"1983","journal-title":"Pain"},{"key":"R34-20250502","doi-asserted-by":"crossref","first-page":"326","DOI":"10.2165\/00003495-199141030-00002","article-title":"Opioid agonist-antagonist drugs in acute and chronic pain states.","volume":"41","author":"Hoskin","year":"1991","journal-title":"Drugs"},{"key":"R35-20250502","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/0028-3908(88)90052-4","article-title":"U50,488: a kappa-selective agent with poor affinity for mu1 opiate binding sites.","volume":"27","author":"Clark","year":"1988","journal-title":"Neuropharmacology"},{"key":"R36-20250502","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1097\/00001756-199806010-00019","article-title":"Mu and kappa opioid receptors in periaqueductal gray and rostral ventromedial medulla.","volume":"9","author":"Gutstein","year":"1998","journal-title":"Neuroreport"},{"key":"R37-20250502","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/38730","article-title":"Cellular mechanism for anti-analgesic action of agonists of the kappa-opioid receptor.","volume":"389","author":"Pan","year":"1997","journal-title":"Nature"},{"key":"R38-20250502","doi-asserted-by":"crossref","first-page":"G434","DOI":"10.1152\/ajpgi.00324.2002","article-title":"Quantitative assessment and characterization of visceral nociception and hyperalgesia in mice.","volume":"284","author":"Kamp","year":"2003","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"R40-20250502","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0014-2999(85)90317-6","article-title":"Rat cold water tail-flick: a novel analgesic test that distinguishes opioid agonists from mixed agonist-antagonists.","volume":"119","author":"Pizziketti","year":"1985","journal-title":"Eur J Pharmacol"},{"key":"R41-20250502","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.neulet.2012.07.018","article-title":"Effects of peripheral \u03ba opioid receptor activation on inflammatory mechanical hyperalgesia in male and female rats.","volume":"524","author":"Auh","year":"2012","journal-title":"Neurosci Lett"},{"key":"R42-20250502","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ejphar.2019.04.011","article-title":"Comparison of the antinociceptive profiles of morphine and oxycodone in two models of inflammatory and osteoarthritic pain in rat.","volume":"854","author":"Garcia","year":"2019","journal-title":"Eur J Pharmacol"},{"key":"R43-20250502","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/0306-4522(91)90396-6","article-title":"Opioid systems in the response to inflammatory pain: sustained blockade suggests role of kappa- but not mu-opioid receptors in the modulation of nociception, behaviour and pathology.","volume":"42","author":"Millan","year":"1991","journal-title":"Neuroscience"},{"key":"R44-20250502","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1093\/emboj\/17.4.886","article-title":"Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50,488H and attenuates morphine withdrawal.","volume":"17","author":"Simonin","year":"1998","journal-title":"EMBO J"},{"key":"R45-20250502","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1136\/gut.43.3.312","article-title":"The kappa opioid receptor is associated with the perception of visceral pain.","volume":"43","author":"Black","year":"1998","journal-title":"Gut"},{"key":"R46-20250502","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/ALN.0b013e3181af6356","article-title":"Analgesic efficacy of peripheral kappa-opioid receptor agonist CR665 compared to oxycodone in a multi-modal, multi-tissue experimental human pain model: selective effect on visceral pain.","volume":"111","author":"Arendt-Nielsen","year":"2009","journal-title":"Anesthesiology"},{"key":"R47-20250502","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1016\/S0140-6736(99)01306-9","article-title":"Visceral pain.","volume":"353","author":"Cervero","year":"1999","journal-title":"Lancet"},{"issue":"suppl 1","key":"R48-20250502","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1097\/j.pain.0000000000000798","article-title":"Reward, motivation, and emotion of pain and its relief.","volume":"158","author":"Porreca","year":"2017","journal-title":"Pain"},{"key":"R49-20250502","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3389\/fpsyt.2013.00072","article-title":"Addiction is a reward deficit and stress surfeit disorder.","volume":"4","author":"Koob","year":"2013","journal-title":"Front Psychiatry"},{"key":"R50-20250502","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.brainres.2009.08.062","article-title":"The dynorphin\/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors.","volume":"1314","author":"Bruchas","year":"2010","journal-title":"Brain Res"},{"key":"R51-20250502","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1152\/physrev.00005.2009","article-title":"Reward processing by the opioid system in the brain.","volume":"89","author":"Le Merrer","year":"2009","journal-title":"Physiol Rev"},{"key":"R52-20250502","first-page":"132","article-title":"Opioid peptides.","volume":"21","author":"Froehlich","year":"1997","journal-title":"Alcohol Health Res World"},{"key":"R53-20250502","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/2045-8118-12-3","article-title":"The effects of beta-endorphin: state change modification.","volume":"12","author":"Veening","year":"2015","journal-title":"Fluids Barriers CNS"},{"key":"R54-20250502","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/BF02244553","article-title":"Beta-endorphin-induced locomotor stimulation and reinforcement are associated with an increase in dopamine release in the nucleus accumbens.","volume":"104","author":"Spanagel","year":"1991","journal-title":"Psychopharmacology (Berl)"},{"key":"R55-20250502","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/BF00690919","article-title":"Rewarding properties of beta-endorphin as measured by conditioned place preference.","volume":"91","author":"Amalric","year":"1987","journal-title":"Psychopharmacology (Berl)"},{"key":"R56-20250502","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/00001756-200403010-00027","article-title":"A critical role for beta-endorphin in cocaine-seeking behavior.","volume":"15","author":"Roth-Deri","year":"2004","journal-title":"Neuroreport"},{"key":"R57-20250502","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.neuropharm.2009.03.013","article-title":"Nicotine anxiogenic and rewarding effects are decreased in mice lacking beta-endorphin.","volume":"56","author":"Trigo","year":"2009","journal-title":"Neuropharmacology"},{"key":"R58-20250502","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1210\/en.2012-1166","article-title":"\u03b2-Endorphin antagonizes the effects of \u03b1-MSH on food intake and body weight.","volume":"153","author":"Dutia","year":"2012","journal-title":"Endocrinology"},{"key":"R59-20250502","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00213-008-1161-4","article-title":"Influence of beta- endorphin on anxious behavior in mice: interaction with EtOH.","volume":"200","author":"Grisel","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"key":"R60-20250502","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1111\/j.1460-9568.2007.05595.x","article-title":"Decreased motivation to eat in mu-opioid receptor-deficient mice.","volume":"25","author":"Papaleo","year":"2007","journal-title":"Eur J Neurosci"},{"key":"R61-20250502","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1111\/j.1460-9568.2004.03581.x","article-title":"Mu-opioid receptor knockout mice show diminished food-anticipatory activity.","volume":"20","author":"Kas","year":"2004","journal-title":"Eur J Neurosci"},{"key":"R62-20250502","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.tins.2015.01.002","article-title":"Understanding opioid reward.","volume":"38","author":"Fields","year":"2015","journal-title":"Trends Neurosci"},{"key":"R63-20250502","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.neuron.2012.10.021","article-title":"The mysterious motivational functions of mesolimbic dopamine.","volume":"76","author":"Salamone","year":"2012","journal-title":"Neuron"},{"key":"R64-20250502","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/0091-3057(91)90210-S","article-title":"Morphine-dopamine interaction: ventral tegmental morphine increases nucleus accumbens dopamine release.","volume":"39","author":"Leone","year":"1991","journal-title":"Pharmacol Biochem Behav"},{"key":"R65-20250502","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/j.1460-9568.2009.06827.x","article-title":"Mu opioid receptor modulation of somatodendritic dopamine overflow: GABAergic and glutamatergic mechanisms.","volume":"30","author":"Chefer","year":"2009","journal-title":"Eur J Neurosci"},{"key":"R66-20250502","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1046\/j.1460-9568.2003.02912.x","article-title":"Basal and morphine-evoked dopaminergic neurotransmission in the nucleus accumbens of MOR- and DOR-knockout mice.","volume":"18","author":"Chefer","year":"2003","journal-title":"Eur J Neurosci"},{"key":"R67-20250502","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0014-2999(02)01812-5","article-title":"Lack of reward and locomotor stimulation induced by heroin in mu-opioid receptor-deficient mice.","volume":"446","author":"Contarino","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"R68-20250502","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1034\/j.1601-183X.2003.00016.x","article-title":"Congenic C57BL\/6 mu opiate receptor (MOR) knockout mice: baseline and opiate effects.","volume":"2","author":"Hall","year":"2003","journal-title":"Genes Brain Behav"},{"key":"R69-20250502","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1007\/s002100000244","article-title":"Morphine self-administration in mu-opioid receptor-deficient mice.","volume":"361","author":"Becker","year":"2000","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"R70-20250502","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/383819a0","article-title":"Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene.","volume":"383","author":"Matthes","year":"1996","journal-title":"Nature"},{"key":"R71-20250502","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1037\/0735-7044.111.6.1324","article-title":"The development of a conditioned place preference to morphine: effects of microinjections into various CNS sites.","volume":"111","author":"Olmstead","year":"1997","journal-title":"Behav Neurosci"},{"key":"R72-20250502","doi-asserted-by":"crossref","first-page":"7225","DOI":"10.1523\/JNEUROSCI.22-16-07225.2002","article-title":"Rewarding and psychomotor stimulant effects of endomorphin-1: anteroposterior differences within the ventral tegmental area and lack of effect in nucleus accumbens.","volume":"22","author":"Zangen","year":"2002","journal-title":"J Neurosci"},{"key":"R73-20250502","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/0091-3057(94)90324-7","article-title":"Differentiation of intracranial morphine self-administration behavior among five brain regions in mice.","volume":"48","author":"David","year":"1994","journal-title":"Pharmacol Biochem Behav"},{"key":"R74-20250502","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s40263-012-0005-2","article-title":"Management of pain in Parkinson\u2019s disease.","volume":"26","author":"Sophie","year":"2012","journal-title":"CNS Drugs"},{"key":"R75-20250502","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.brainresbull.2014.06.003","article-title":"Dopaminergic modulation of neuropathic pain: analgesia in rats by a D2-type receptor agonist.","volume":"106","author":"Cobacho","year":"2014","journal-title":"Brain Res Bull"},{"key":"R76-20250502","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/nature04172","article-title":"Morphine reward in dopamine-deficient mice.","volume":"438","author":"Hnasko","year":"2005","journal-title":"Nature"},{"key":"R77-20250502","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1369-1600.2010.00249.x","article-title":"Implication of dopaminergic projection from the ventral tegmental area to the anterior cingulate cortex in \u03bc-opioid-induced place preference.","volume":"15","author":"Narita","year":"2010","journal-title":"Addict Biol"},{"key":"R78-20250502","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0166-4328(01)00164-4","article-title":"Effects of dopamine antagonists with different receptor blockade profiles on morphine-induced place preference in male mice.","volume":"121","author":"Manzanedo","year":"2001","journal-title":"Behav Brain Res"},{"key":"R79-20250502","doi-asserted-by":"crossref","first-page":"9499","DOI":"10.1523\/JNEUROSCI.21-23-09499.2001","article-title":"Absence of delta -9-tetrahydrocannabinol dysphoric effects in dynorphin-deficient mice.","volume":"21","author":"Zimmer","year":"2001","journal-title":"J Neurosci"},{"key":"R80-20250502","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00213-010-1946-0","article-title":"Lack of a rewarding effect and a locomotor-enhancing effect of the selective \u03bc-opioid receptor agonist amidino-TAPA.","volume":"212","author":"Mizoguchi","year":"2010","journal-title":"Psychopharmacology (Berl)"},{"key":"R81-20250502","doi-asserted-by":"crossref","first-page":"7285","DOI":"10.1523\/JNEUROSCI.18-18-07285.1998","article-title":"Activity of the delta-opioid receptor is partially reduced, whereas activity of the kappa-receptor is maintained in mice lacking the mu-receptor.","volume":"18","author":"Matthes","year":"1998","journal-title":"J Neurosci"},{"key":"R82-20250502","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0306-4522(01)00333-5","article-title":"Naloxone fails to produce conditioned place aversion in mu-opioid receptor knock-out mice.","volume":"106","author":"Skoubis","year":"2001","journal-title":"Neuroscience"},{"key":"R83-20250502","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.brainres.2009.09.074","article-title":"Dynorphin, stress, and depression.","volume":"1314","author":"Knoll","year":"2010","journal-title":"Brain Res"},{"key":"R84-20250502","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/cne.21464","article-title":"Coexpression of prodynorphin and corticotrophin-releasing hormone in the rat central amygdala: evidence of two distinct endogenous opioid systems in the lateral division.","volume":"504","author":"Marchant","year":"2007","journal-title":"J Comp Neurol"},{"key":"R85-20250502","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s002210050545","article-title":"Role of dynorphin and enkephalin in the regulation of striatal output pathways and behavior.","volume":"123","author":"Steiner","year":"1998","journal-title":"Exp Brain Res"},{"key":"R86-20250502","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1523\/JNEUROSCI.4458-07.2008","article-title":"The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system.","volume":"28","author":"Land","year":"2008","journal-title":"J Neurosci"},{"key":"R87-20250502","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1101\/lm.037317.114","article-title":"Reward processing by the dorsal raphe nucleus: 5-HT and beyond.","volume":"22","author":"Luo","year":"2015","journal-title":"Learn Mem"},{"key":"R88-20250502","doi-asserted-by":"crossref","first-page":"12917","DOI":"10.1523\/JNEUROSCI.2444-15.2015","article-title":"Kappa opioid receptor-induced aversion requires p38 MAPK activation in VTA dopamine neurons.","volume":"35","author":"Ehrich","year":"2015","journal-title":"J Neurosci"},{"key":"R89-20250502","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1038\/npp.2013.171","article-title":"Kappa opioid receptors on dopaminergic neurons are necessary for kappa-mediated place aversion.","volume":"38","author":"Chefer","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"R90-20250502","doi-asserted-by":"crossref","first-page":"8908","DOI":"10.1523\/JNEUROSCI.1526-08.2008","article-title":"Midbrain dopamine neurons: projection target determines action potential duration and dopamine D2 receptor inhibition.","volume":"28","author":"Margolis","year":"2008","journal-title":"J Neurosci"},{"key":"R91-20250502","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.biopsych.2005.09.018","article-title":"The mesolimbic dopamine reward circuit in depression.","volume":"59","author":"Nestler","year":"2006","journal-title":"Biol Psychiatry"},{"key":"R92-20250502","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1080\/10550490902925862","article-title":"The kappa-opiate receptor impacts the pathophysiology and behavior of substance use.","volume":"18","author":"Mysels","year":"2009","journal-title":"Am J Addict"},{"key":"R93-20250502","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00213-014-3641-z","article-title":"Behavioural and neurochemical assessment of salvinorin A abuse potential in the rat.","volume":"232","author":"Serra","year":"2015","journal-title":"Psychopharmacology (Berl)"},{"key":"R94-20250502","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jphs.2016.05.007","article-title":"Nalfurafine hydrochloride, a selective \u03ba opioid receptor agonist, has no reinforcing effect on intravenous self-administration in rhesus monkeys.","volume":"132","author":"Ruan","year":"2016","journal-title":"J Pharmacol Sci"},{"key":"R95-20250502","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.neuron.2019.02.029","article-title":"Pain- induced negative affect is mediated via recruitment of the nucleus accumbens kappa opioid system.","volume":"102","author":"Massaly","year":"2019","journal-title":"Neuron"},{"key":"R96-20250502","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.neuron.2015.08.019","article-title":"Distinct subpopulations of nucleus accumbens dynorphin neurons drive aversion and reward.","volume":"87","author":"Al-Hasani","year":"2015","journal-title":"Neuron"},{"key":"R97-20250502","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.neuropharm.2013.10.005","article-title":"Kappa opioid receptor activation decreases inhibitory transmission and antagonizes alcohol effects in rat central amygdala.","volume":"77","author":"Gilpin","year":"2014","journal-title":"Neuropharmacology"},{"key":"R98-20250502","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.biopsych.2011.03.017","article-title":"Kappa opioid receptor signaling in the basolateral amygdala regulates conditioned fear and anxiety in rats.","volume":"70","author":"Knoll","year":"2011","journal-title":"Biol Psychiatry"},{"key":"R99-20250502","doi-asserted-by":"crossref","first-page":"e8528","DOI":"10.1371\/journal.pone.0008528","article-title":"CRF1-R activation of the dynorphin\/kappa opioid system in the mouse basolateral amygdala mediates anxiety-like behavior.","volume":"4","author":"Bruchas","year":"2009","journal-title":"PLoS One"},{"key":"R100-20250502","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.brainres.2005.04.076","article-title":"mu- opioids disinhibit and kappa-opioids inhibit serotonin efflux in the dorsal raphe nucleus.","volume":"1049","author":"Tao","year":"2005","journal-title":"Brain Res"},{"key":"R101-20250502","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.neuron.2011.06.011","article-title":"Selective p38\u03b1 MAPK deletion in serotonergic neurons produces stress resilience in models of depression and addiction.","volume":"71","author":"Bruchas","year":"2011","journal-title":"Neuron"},{"key":"R102-20250502","doi-asserted-by":"crossref","first-page":"19168","DOI":"10.1073\/pnas.0910705106","article-title":"Activation of the kappa opioid receptor in the dorsal raphe nucleus mediates the aversive effects of stress and reinstates drug seeking.","volume":"106","author":"Land","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"R103-20250502","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0024-3205(92)90077-3","article-title":"Stress-induced changes in brain Met-enkephalin, Leu-enkephalin and dynorphin concentrations.","volume":"51","author":"Nabeshima","year":"1992","journal-title":"Life Sci"},{"key":"R104-20250502","doi-asserted-by":"crossref","first-page":"ra117","DOI":"10.1126\/scisignal.aai8441","article-title":"Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria.","volume":"9","author":"Brust","year":"2016","journal-title":"Sci Signal"},{"key":"R105-20250502","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/npp.2015.142","article-title":"Stress- induced reinstatement of drug seeking: 20 years of progress.","volume":"41","author":"Mantsch","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"R106-20250502","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00213-008-1122-y","article-title":"Stress-induced reinstatement of cocaine seeking is mediated by the kappa opioid system.","volume":"200","author":"Redila","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"key":"R107-20250502","doi-asserted-by":"crossref","first-page":"5674","DOI":"10.1523\/JNEUROSCI.23-13-05674.2003","article-title":"Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses.","volume":"23","author":"McLaughlin","year":"2003","journal-title":"J Neurosci"},{"key":"R108-20250502","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.neubiorev.2018.09.008","article-title":"Addiction and stress: an allostatic view.","volume":"106","author":"Koob","year":"2019","journal-title":"Neurosci Biobehav Rev"},{"key":"R109-20250502","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ddmod.2009.04.002","article-title":"Hedonic homeostatic dysregulation as a driver of drug-seeking behavior.","volume":"5","author":"Koob","year":"2008","journal-title":"Drug Discov Today Dis Models"},{"key":"R110-20250502","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41386-018-0292-5","article-title":"NIDA\u2019s medication development priorities in response to the opioid crisis: ten most wanted.","volume":"44","author":"Rasmussen","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"R111-20250502","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/bja\/aeq406","article-title":"Paracetamol and selective and non-selective non-steroidal anti-inflammatory drugs for the reduction in morphine-related side-effects after major surgery: a systematic review.","volume":"106","author":"Maund","year":"2011","journal-title":"Br J Anaesth"},{"key":"R112-20250502","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1172\/JCI88760","article-title":"Alternatively spliced mu opioid receptor C termini impact the diverse actions of morphine.","volume":"127","author":"Xu","year":"2017","journal-title":"J Clin Invest"},{"key":"R113-20250502","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1126\/science.aai8636","article-title":"A nontoxic pain killer designed by modeling of pathological receptor conformations.","volume":"355","author":"Spahn","year":"2017","journal-title":"Science"},{"key":"R114-20250502","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0091-3057(98)00017-3","article-title":"Kappa antinociceptive activity of spiradoline in the cold-water tail-flick assay in rats.","volume":"60","author":"Briggs","year":"1998","journal-title":"Pharmacol Biochem Behav"},{"key":"R115-20250502","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1124\/jpet.114.216820","article-title":"The G protein-biased -opioid receptor agonist RB-64 is analgesic with a unique spectrum of activities in vivo.","volume":"352","author":"White","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"R116-20250502","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.bmc.2007.10.067","article-title":"Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers.","volume":"16","author":"Munro","year":"2008","journal-title":"Bioorg Med Chem"},{"key":"R117-20250502","doi-asserted-by":"crossref","first-page":"36703","DOI":"10.1074\/jbc.M113.504381","article-title":"Development of functionally selective, small molecule agonists at kappa opioid receptors.","volume":"288","author":"Zhou","year":"2013","journal-title":"J Biol Chem"},{"key":"R118-20250502","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1037\/a0013088","article-title":"Micro\/kappa opioid interactions in rhesus monkeys: implications for analgesia and abuse liability.","volume":"16","author":"Negus","year":"2008","journal-title":"Exp Clin Psychopharmacol"},{"key":"R119-20250502","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.neuropharm.2003.11.003","article-title":"Functional interaction among opioid receptor types: up-regulation of mu- and delta-opioid receptor functions after repeated stimulation of kappa-opioid receptors.","volume":"46","author":"Khotib","year":"2004","journal-title":"Neuropharmacology"},{"key":"R120-20250502","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0304-3959(98)00237-1","article-title":"Enadoline, a selective kappa-opioid receptor agonist shows potent antihyperalgesic and antiallodynic actions in a rat model of surgical pain.","volume":"80","author":"Field","year":"1999","journal-title":"Pain"},{"key":"R121-20250502","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.drugalcdep.2006.01.013","article-title":"Nalbuphine is effective in decreasing the rewarding effect induced by morphine in rats.","volume":"84","author":"Tao","year":"2006","journal-title":"Drug Alcohol Depend"},{"key":"R122-20250502","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/7854_2016_448","article-title":"The abuse potential of prescription opioids in humans-closing in on the first century of research.","volume":"34","author":"Walsh","year":"2017","journal-title":"Curr Top Behav Neurosci"},{"key":"R123-20250502","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/S0022-5347(25)00400-8","article-title":"Comparative evaluation of morphine, pentazocine and ciramadol in postaddicts.","volume":"240","author":"Preston","year":"1987","journal-title":"J Pharmacol Exp Ther"},{"key":"R124-20250502","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0022-3565(25)22416-8","article-title":"Comparing the subjective, psychomotor and physiological effects of intravenous butorphanol and morphine in healthy volunteers.","volume":"270","author":"Zacny","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"R125-20250502","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00213-007-0948-z","article-title":"Evaluation of the mu and kappa opioid actions of butorphanol in humans through differential naltrexone blockade.","volume":"196","author":"Walsh","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"key":"R126-20250502","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0022-3565(25)10212-7","article-title":"Differential naltrexone antagonism of hydromorphone and pentazocine effects in human volunteers.","volume":"264","author":"Preston","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"R127-20250502","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0022-3565(25)22067-5","article-title":"Butorphanol-precipitated withdrawal in opioid-dependent human volunteers.","volume":"246","author":"Preston","year":"1988","journal-title":"J Pharmacol Exp Ther"},{"key":"R128-20250502","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0022-3565(25)24168-4","article-title":"Antagonist effects of nalbuphine in opioid-dependent human volunteers.","volume":"248","author":"Preston","year":"1989","journal-title":"J Pharmacol Exp Ther"},{"key":"R129-20250502","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S0022-3565(25)39357-2","article-title":"Precipitated withdrawal by pentazocine in methadone-maintained volunteers.","volume":"267","author":"Strain","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"R130-20250502","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1021\/jm301543e","article-title":"Orvinols with mixed kappa\/mu opioid receptor agonist activity.","volume":"56","author":"Greedy","year":"2013","journal-title":"J Med Chem"},{"key":"R132-20250502","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/nrd.2017.178","article-title":"Trends in GPCR drug discovery: new agents, targets and indications.","volume":"16","author":"Hauser","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"R133-20250502","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00018-004-4462-3","article-title":"G-protein signaling: back to the future.","volume":"62","author":"McCudden","year":"2005","journal-title":"Cell Mol Life Sci"},{"key":"R134-20250502","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ceb.2013.10.008","article-title":"Recent developments in biased agonism.","volume":"27","author":"Wisler","year":"2014","journal-title":"Curr Opin Cell Biol"},{"key":"R136-20250502","first-page":"11614","article-title":"Stress-induced p38 mitogen-activated protein kinase activation mediates -opioid-dependent.","volume":"27","author":"Bruchas","year":"2007","journal-title":"Dysphoria"},{"key":"R137-20250502","doi-asserted-by":"crossref","first-page":"18081","DOI":"10.1074\/jbc.M513640200","article-title":"Kappa opioid receptor activation of p38 MAPK is GRK3- and arrestin-dependent in neurons and astrocytes.","volume":"281","author":"Bruchas","year":"2006","journal-title":"J Biol Chem"},{"key":"R138-20250502","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1124\/jpet.118.255661","article-title":"Preclinical testing of nalfurafine as an opioid-sparing adjuvant that potentiates analgesia by the mu opioid receptor-targeting agonist morphine.","volume":"371","author":"Kaski","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"R139-20250502","doi-asserted-by":"crossref","first-page":"823","DOI":"10.5414\/CP201852","article-title":"One year long-term study on abuse liability of nalfurafine in hemodialysis patients.","volume":"51","author":"Ueno","year":"2013","journal-title":"Int J Clin Pharmacol Ther"},{"key":"R140-20250502","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2147\/CCID.S55942","article-title":"Nalfurafine hydrochloride to treat pruritus: a review.","volume":"8","author":"Inui","year":"2015","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"R141-20250502","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1007\/s00213-020-05519-7","article-title":"Quantification of observable behaviors induced by typical and atypical kappa-opioid receptor agonists in male rhesus monkeys.","volume":"237","author":"Huskinson","year":"2020","journal-title":"Psychopharmacology (Berl)"},{"key":"R142-20250502","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s00213-020-05473-4","article-title":"Kappa opioid agonists reduce oxycodone self-administration in male rhesus monkeys.","volume":"237","author":"Zamarripa","year":"2020","journal-title":"Psychopharmacology (Berl)"},{"key":"R143-20250502","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1097\/FBP.0000000000000581","article-title":"The kappa-opioid receptor agonist, nalfurafine, blocks acquisition of oxycodone self-administration and oxycodone\u2019s conditioned rewarding effects in male rats.","volume":"31","author":"Zamarripa","year":"2020","journal-title":"Behav Pharmacol"},{"key":"R144-20250502","doi-asserted-by":"crossref","first-page":"108244","DOI":"10.1016\/j.neuropharm.2020.108244","article-title":"Nalfurafine modulates the reinforcing effects of oxycodone in male and female adolescent C57BL\/6J mice.","volume":"176","author":"Zhang","year":"2020","journal-title":"Neuropharmacology"},{"key":"R145-20250502","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1038\/s41386-019-0423-7","article-title":"Role of RGS12 in the differential regulation of kappa opioid receptor-dependent signaling and behavior.","volume":"44","author":"Gross","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"R146-20250502","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1177\/0269881117742100","article-title":"Regulator of G protein signaling-12 modulates the dopamine transporter in ventral striatum and locomotor responses to psychostimulants.","volume":"32","author":"Gross","year":"2018","journal-title":"J Psychopharmacol"},{"key":"R147-20250502","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1177\/0269881120944160","article-title":"Genetic deletion of Rgs12 in mice affects serotonin transporter expression and function in vivo and ex vivo.","volume":"34","author":"White","year":"2020","journal-title":"J Psychopharmacol"},{"key":"R148-20250502","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.neuropharm.2014.07.016","article-title":"Salvinorin A regulates dopamine transporter function via a kappa opioid receptor and ERK1\/2-dependent mechanism.","volume":"86","author":"Kivell","year":"2014","journal-title":"Neuropharmacology"},{"key":"R149-20250502","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1038\/sj.emboj.7601659","article-title":"Selective role for RGS12 as a Ras\/Raf\/MEK scaffold in nerve growth factor-mediated differentiation.","volume":"26","author":"Willard","year":"2007","journal-title":"EMBO J"},{"key":"R150-20250502","doi-asserted-by":"crossref","first-page":"396","DOI":"10.2174\/138620708784534770","article-title":"A high throughput fluorescence polarization assay for inhibitors of the GoLoco motif\/G-alpha interaction.","volume":"11","author":"Kimple","year":"2008","journal-title":"Comb Chem High Throughput Screen"},{"key":"R151-20250502","first-page":"30215","article-title":"Critical assessment of G protein-biased agonism at the mu-opioid receptor.","volume":"S0165\u20136147","author":"Gillis","year":"2020","journal-title":"Trends Pharmacol Sci"}],"container-title":["Anesthesia &amp; Analgesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1213\/ANE.0000000000005309","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:35:35Z","timestamp":1786113335000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1213\/ANE.0000000000005309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,16]]},"references-count":144,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1213\/ane.0000000000005309","relation":{},"ISSN":["0003-2999"],"issn-type":[{"value":"0003-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12,16]]}}}